Global COVID 19 Impact On Vaccines & Drugs Market Trends
A growing quantity of clinical studies
Growing numbers of clinical studies fuel the market expansion for drugs and vaccines. For example, the Chinese National Medical Products Administration approved two COVID-19 inactivated vaccines for phase 1 and phase 2 combined studies on April 17, 2020. Furthermore, Pfizer and BioNTech, two significant pharmaceutical companies, announced a joint venture in March 2020 to jointly develop and commercialize the coronavirus vaccine. Similarly, Johnson & Johnson declared in April 2020 that they would manufacture up to 900 million COVID-19 vaccinations by the first quarter of 2021. As a result, the pandemic's emergence has sparked investor interest in the vaccine and medication markets, which has fueled their expansion.
Funding from worldwide foundations and governments
Encouraging manufacturers to engage in large-scale production is necessary to ensure sufficient production of SARS-CoV-2 vaccines.
Numerous international organizations, including CEPI, Gavi, and WHO, have stepped forward to quicken the process. Nevertheless, in light of the COVID-19 pandemic scenario, far more robust measures are required. Even before receiving definitive evidence, the Bill and Melinda Gates Foundation announced plans to assist in funding the production of seven promising vaccines in April 2020. The foundation's goal is to increase manufacturing while testing is underway. A number of other large pharmaceutical companies are working on the COVID-19 vaccine, which is also the most promising Moderna program. Sanofi is in the process of forming two partnerships: one with Translate Bio and the other with the federal government. Johnson & Johnson has committed to scaling up production for its federally funded initiative to produce one billion doses.